Teva (NYSE:TEVA) files a petition with the FDA requesting the agency task an outside panel to...

Teva (NYSE:TEVA) files a petition with the FDA requesting the agency task an outside panel to evaluate the safety of Biogen's (NASDAQ:BIIB) multiple sclerosis drug, BG-12, before approval due to concerns over potential risks to the kidney. The drug is a potential competitor to TEVA's Copaxone, and if the request is granted, the drug's launch could be delayed.